Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025)

NewAmsterdam Pharma's Other financing activities history spans 2 years, with the latest figure at $1.6 million for Q1 2025.

  • For Q1 2025, Other financing activities rose 207.96% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 207.96%, while the annual FY2025 figure was $1.6 million, 207.96% up from the prior year.
  • Other financing activities for Q1 2025 was $1.6 million at NewAmsterdam Pharma, up from $515000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.6 million in Q1 2025 and bottomed at $515000.0 in Q1 2024.